Pharming Group NV has seen its first quarterly net profit in 2018 driven by sales of Ruconest – its own drug to which the company bought back the rights in 2016.
In Q1 2018, Pharming saw a net profit of €3.3m flow in from sales of Ruconest (conestat alfa). In the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?